

簡歷

林家齊 Chia-Chi (Josh) Lin, MD, PhD

現職：

1. 台大醫學院臨床醫學研究所教授
2. 台大醫院腫瘤醫學部早期臨床試驗病房主任
3. 台大醫院臨床試驗中心代理主任



經歷：

1. 美國德州聖安東尼奧，癌症治療及研究中心(Cancer Therapy and Research Center, CTRC)，藥物研發學院 (Institute for Drug Development, IDD) 進階癌症藥物研發臨床研究員，2006 年至 2007 年
2. 美國亞利桑那州鳳凰城，轉譯基因體研究中心 (Translational Genomics Research Institute, TGen)，臨床研究中心 (TGen Clinical Research Service, TCRS) 癌症藥物開發學者，2007 年至 2008 年

學歷：

1. 國立台灣大學醫學系 (M.D.)，1994 年
2. 國立台灣大學臨床醫學研究所 (Ph.D.)，2006 年

研究主題：

1. 肺癌、食道癌、甲狀腺癌的藥物治療
2. 癌症新藥早期臨床試驗 (科技部台灣臨床試驗聯盟：台灣癌症早期臨床試驗聯盟計畫主持人，2011 年至 2021 年)

榮譽獎勵：

1. 台灣癌症醫學會徐千田癌症研究傑出獎，2020 年

代表著作 (最近五年)：

1. Minami H,* Ando Y, Ma B, Lee J-H, Momota H, Fujiwara Y, Li L, Fukino K, Ito K, Tajima T, Mori A, Lin C-C.* A phase 1, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Sci 107:1477-83, 2016 (*equal contribution)
2. Lin C-C, Shih J-Y, Yu C-J, Ho C-C, Liao W-Y, Lee J-H, Tsai T-H, Su K-Y, Hsieh M-S, Chang Y-L, Bai Y-Y, Huang DD, Thress KS, Yang C-H. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med 6:106-17, 2018

3. Doi T, Yang C-H, Shitara K, Naito Y, Cheng A-L, Sarashina A, Pronk L-C, Takeuchi Y, Lin C-C.* Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors. *Target Oncol* 14:57-65, 2019 (*corresponding author)
4. Lin C-C, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su W-C, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. *Br J Cancer* 121:131-8, 2019
5. Lee J-H, Chen W-W, Hsu C-H, Yen Y-H, Yang C-H, Cheng A-L, Sasaki S, Chiu L-Y, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin C-C.* A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. *Invest New Drugs* 38:99-110, 2020 (*corresponding author)
6. de Bono JJ*, Lin C-C*, Chen L-T, Corral J, Michalarea V, Rihawi K, Ong M, Lee J-H, Hsu C-H, Yang C-H, Shiah H-S, Yen C-J, Anthony A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner R-G, Strelkowa N, Huang DC-L, Bogenrieder T, Twelves C, Cheng A-L. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. *Br J Cancer* 122:1324-32, 2020 (*equal contribution)
7. Lin C-C*, Yang TS*, Yen CJ, Cheng R, Liu J, Hsu C. Safety and preliminary efficacy of ramucirumab in combination with FOLFOX4 in patients with advanced hepatocellular carcinoma: A nonrandomized, open-label, phase Ib study. *Oncologist* 25:e1921-9, 2020 (*equal contribution)
8. Shiah H-S, Chiang N-J, Lin C-C*, Yen C-J, Tsai H-J, Wu S-Y, Su W-C, Chang K-Y, Wang C-C, Chang J-Y, Chen L-T*. Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. *Oncologist* 26:e567-79, 2021 (*corresponding author)
9. Lin C-C, Doi T, Muro K, Hou M-M, Esaki T, Hara H, Chung HC, Helwig C, Dussault I, Osada M, Kondo S. Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in 1 patients with esophageal squamous cell carcinoma: results from a phase 1 cohort in Asia. *Target Oncol* 16:447-59, 2021